AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00747890 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified tonsillectomy
Description: * Tonsillectomy~* Uvulectomy~* Soft palatal resection~* Lifestyle counselling by physician: General (e.g. avoidance of smoking, alcohol drinking) and nutritional education, and sleeping positional guidance
Study NCT00747890 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lifestyle counselling by physician
Description: General (e.g. avoidance of smoking, alcohol drinking) and nutritional education, and sleeping positional guidance.
Study NCT00126542 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00126542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally
Study NCT00126542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02425267 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation (Physiotherapy)
Description: The training program will be carried out twice a day, and at every day during the eight-week program, either by telerehabilitation or in the clinic or by autonomous unsupervised way. During weeks 1, 3 and 5, the patient will perform his/her exercises twice a week by telerehabilitation/clinic and the other without supervision. During the other weeks (2, 4, 6, 7, 8), the patient will benefit from one exercise session by telerehabilitation/clinic per week and will perform all other without supervision. Supervised sessions allow the therapist and the patient to adjust the program in case of problems and to ensure a smooth implementation of the program.
Study NCT00393627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Education Program
Description: The Sleep Education Program (SEP) is conducted by a licensed MS- or PhD-level mental health professional experienced in working with persons with dementia and their caregivers. The therapist meets with the AFH owner/operator and staff for four weekly sessions at the AFH. The SEP content includes information about the causes of sleep problems in dementia, and provides staff with assistance in developing customized resident behavioral sleep plans focused on environmental (light and noise), dietary (eliminating caffeine and excessive nighttime fluids), and sleep scheduling (reducing afternoon/ evening napping; consistent, appropriate bed and rising times) factors that are commonly associated with resident nighttime awakenings. A written manual is used.
Study NCT00393627 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sleep Education Program
Description: The Sleep Education Program (SEP) is conducted by a licensed MS- or PhD-level mental health professional experienced in working with persons with dementia and their caregivers. The therapist meets with the AFH owner/operator and staff for four weekly sessions at the AFH. The SEP content includes information about the causes of sleep problems in dementia, and provides staff with assistance in developing customized resident behavioral sleep plans focused on environmental (light and noise), dietary (eliminating caffeine and excessive nighttime fluids), and sleep scheduling (reducing afternoon/ evening napping; consistent, appropriate bed and rising times) factors that are commonly associated with resident nighttime awakenings. A written manual is used.
Study NCT02386371 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tumorectomy
Description: Tumorectomy will be performed according to the current standards, obtaining clear margins. The axillary lymph node control will depend on the initial management (clinical and ultrasound) of these N0 patients, chosen by the teams.
Study NCT02386371 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intra Operative Radiotherapy
Description: After the excision of the tumor, IORT will be delivered. A single dose of 20 Gy by 50 kV photons (Intrabeam™) will be administered in tumor bed. The addition of IORT does not modify the surgical procedure
Study NCT02135783 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decompressive Craniectomy
Description: A portion of frontal,temporal, and parietal bone was removed by craniectomy and the size of decompression was about 10x12 cm2.Intracerebral hematoma was evacuated by transcortical approach with the aid of a surgical microscope.
Study NCT02135783 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non-Decompressive Craniectomy
Description: a simple hematoma removal by osteoplastic craniotomy group (HR) or Intracerebral hematoma was evacuated by transcortical approach with the aid of a surgical neuroendoscopyand the size of decompression was about 3x2.5 cm2.
Study NCT03610633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: The neuropeptide oxytocin (OT) increases social approach, trust, and reduces anxiety to social stress.
Study NCT03610633 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution.
Study NCT02374502 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention
Description: 'Brief Intervention' is the term used to mean verbal advice, discussion, negotiation or encouragement, with or without written or other support or follow-up. 'Brief Interventions' provide a structured way to deliver advice and involve the provision of formal help and follow-up. They aim to equip people with tools to change attitudes and handle underlying problems.
Study NCT02519296 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure Therapy
Description: 8 sessions with prolonged exposure therapy and fMRI.
Study NCT02519296 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Description: fMRI.
Study NCT02519296 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fMRI
Description: Functional Magnetic Resonance Imaging of the brain
Study NCT01126021 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentives
Description: Participants are eligible for incentives if they participate in at least 30 games per day.
Study NCT01126021 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No incentives
Description: Participants will be given training and access to the software to participate in mental exercises but will not be given financial incentives for participation.
Study NCT01517022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine replacement therapy
Description: nicotine replacement therapy 2mg for patients cessation arm for period of 6 weeks
Study NCT03364816 — intervention group
Intervention type: PROCEDURE
Intervention: TDR
Description: total artificial disc replacement
Study NCT02425267 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation (Physiotherapy)
Description: The training program will be carried out twice a day, and at every day during the eight-week program, either by telerehabilitation or in the clinic or by autonomous unsupervised way. During weeks 1, 3 and 5, the patient will perform his/her exercises twice a week by telerehabilitation/clinic and the other without supervision. During the other weeks (2, 4, 6, 7, 8), the patient will benefit from one exercise session by telerehabilitation/clinic per week and will perform all other without supervision. Supervised sessions allow the therapist and the patient to adjust the program in case of problems and to ensure a smooth implementation of the program.
Study NCT01419249 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: Subjects with pre-established diagnosis of IGHD and TS and were treated with r-hGH therapy for 1 year, will be observed in this retrospective cohort study wherein blood sampling will performed for genotyping of the various genetic markers along with collection of retrospective data relative to the r-hGH treatment.
Study NCT04123366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Oral tablet
Study NCT04123366 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion
Study NCT00070122 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00070122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT00070122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03380325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost infusion
Description: Iloprost is a stable prostacyclin analogue
Study NCT00021541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given orally, 200 mg/m\^2/dose BSA every 12 hours by mouth (po) daily x 21 days, Course is every 28 days
Study NCT00021541 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients receive oral placebo every 12 hours on days 1-21. Courses repeat as in arm I.
Study NCT02355262 — intervention group
Intervention type: OTHER
Intervention: Informational Intervention
Description: Receive CATCH-UP intervention
Study NCT04315961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinded drug dose conditions
Description: Capsules will contain commonly prescribed or over-the-counter drugs or placebo. Capsules in this study may contain sedatives, muscle relaxants, or anti-anxiety medications, stimulant drugs/weight loss medications, or antihistamines which must remain blinded for the purposes of this study.
Study NCT04315961 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Blinded drug dose conditions
Description: Capsules will contain commonly prescribed or over-the-counter drugs or placebo. Capsules in this study may contain sedatives, muscle relaxants, or anti-anxiety medications, stimulant drugs/weight loss medications, or antihistamines which must remain blinded for the purposes of this study.
Study NCT01950598 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Boston KPro type I - fresh graft
Description: Boston KPro mounted on fresh corneal carrier graft for implantation
Study NCT01950598 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Boston KPro type I surgery - frozen graft
Description: Boston KPro mounted on frozen corneal carrier graft for implantation
Study NCT02799979 — intervention group
Intervention type: DEVICE
Intervention: 3D right ventricular imaging echocardiographic
Description: Echocardiographic data (3D right ventricular imaging echocardiographic) will be collected at baseline and after 6months.
Study NCT04098913 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced screen-based media use
Description: Participants must remove all recreational screen-based media use beyond 3 hours/week. This includes all recreational screen-based media use inside and outside the household. As a tool to comply with the intervention the families will hand-over all portable screen-based media devices. In return, each participant who own a smartphone will receive a regular cell-phone which can only make phone calls and send text messages. For a maximum of ½ an hour a day, adult participants may use screen-based media for necessary contact/errands. If one of the adult participants can not hand over their smartphones due to daily use for work purposes we will install an app tracking screen use on these devices.
Study NCT03992482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Immune Globulin (IVIG)
Description: Intravenous Immunoglobulin (IVIG), 4 mg/ml (0.4%) eye drops two times a day for eight weeks
Study NCT04456010 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Eligible patients will be selected from our electronical database and invited via email to participate.
Study NCT03809923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine and dexmedetomidine infusion
Description: Patients received IV bolus infusion of lidocaine (2%) 1.5 mg/kg and dexmedetomidine 0.5 µg/kg diluted with normal saline to 20 ml in the LD group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion at rate of lidocaine 1.5 mg/kg and dexmedetomidine 0.4 µg/kg made up to 20 mL every hour until 30 min before the end of operation, respectively.
Study NCT03809923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline infusion
Description: Patients received 20 ml normal saline and 20 ml normal saline in the CON group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion 20 ml normal saline and 20 ml normal saline every hour until 30 min before the end of surgery
Study NCT03809923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine infusion
Description: patients received an IV bolus infusion of lidocaine (2%) 1.5 mg/kg made to 20ml with normal saline and 20ml normal saline respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion of lidocaine 1.5 mg/kg made up to 20ml and 20ml normal saline every hour until 30 min before the end of operation, respectively.
Study NCT03809923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Description: Patients received IV bolus infusion of dexmedetomidine 0.5 μg/kg made to 20ml with normal saline and 20ml normal saline respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion of dexmedetomidine 0.4μg/kg made up to 20ml and 20ml normal saline every houruntil 30 min before the end of operation, respectively.
Study NCT00657254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexavar (Sorafenib, BAY43-9006)
Description: Bay 43-9006 400mg (2 x 200mg tablets) orally twice daily until withdrawal.
Study NCT01177332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: 2 hours cycling exercise at 50 % of maximal power output
Study NCT01177332 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: exercise
Description: 2 hours cycling exercise at 50 % of maximal power output
Study NCT02401139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Study NCT02401139 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02909179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mCARE-II
Description: mCARE-II is a package of interventions that provides guided client enumeration and follow-up support to community health workers, automated workflow scheduling, risk assessment, client prioritization and stratification and client-based demand generation messaging. These features are incorporated into a platform called OpenSRP, which integrates text message reminders, scheduling, and form submissions on the server side, and displays schedules and client lists on a tablet-based application for community health workers.
Study NCT00704808 — intervention group
Intervention type: PROCEDURE
Intervention: Primary surgical treatment
Description: Primary surgery for tumor resection.
Study NCT00704808 — intervention group
Intervention type: RADIATION
Intervention: Radiotherapy
Description: Radiotherapy is given with concomitant temozolomide. Dosing according to European Summary of Product Characteristics.
Study NCT00704808 — intervention group
Intervention type: DRUG
Intervention: Temozolomide
Description: Temozolomide is first given with concomitant radiotherapy, and then as monotherapy (adjuvant chemotherapy). Dosing according to European Summary of Product Characteristics.
Study NCT02653378 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DIET
Description: 25% Energy Depletion by Diet only for 3 Days
Study NCT02653378 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EX
Description: 25% Energy Depletion by Exercise only for 3 Days
Study NCT01242020 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Perflutren Lipid Microsphere Injectable Suspension
Description: 1.3 mL activated DEFINITY® diluted in 50 mL of preservative-free saline will be used
Study NCT03777579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS001，an engineered anti-PD-1 antibody
Description: JS001 at a fixed dose of 240 milligrams via intravenous (IV) infusion on Days 1 of each 21-day cycle until disease progression or unacceptable toxicity.
Study NCT03201627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: To observe whether lithium carbonate has protective role on the brain of Niemann-Pick disease C1
Study NCT04466228 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: non-invasive transcranial electrical stimulation
Description: Non-invasive transcranial electrical stimulation across the prefrontal cortex.
Study NCT04466228 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive transcranial electrical stimulation
Description: Non-invasive transcranial electrical stimulation across the prefrontal cortex.
Study NCT03777579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel at a starting dose of 125mg per square meter via IV infusion on Days 1, 8 of each 21-day cycle. Nab-Paclitaxel will be administered until disease progression or unacceptable toxicity.
Study NCT03777579 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel at a starting dose of 125mg per square meter via IV infusion on Days 1, 8 of each 21-day cycle. Nab-Paclitaxel will be administered until disease progression or unacceptable toxicity.
Study NCT03777579 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered via intravenous (IV) infusion on Days 1 of each 21-day cycle until disease progression or unacceptable toxicity.
Study NCT04454996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tong-jiang granules
Description: This is a kind of compound Chinese medicine granules, 1 bag each time, 3 times a day, treatment for 4 weeks.
Study NCT04454996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chang 'an II Recipe
Description: This is Chang 'an II Prescription granule, 1 bag each time, 3 times a day, treatment for 4 weeks.
Study NCT04454996 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: The placebo of tong-jiang granules
Description: This is a granule, containing 5% tongyu granule active drug,1 bag each time, 3 times a day, treatment for 4 weeks.
Study NCT01119625 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal vaccine GSK1024850A
Description: Intramuscular injection, one dose
Study NCT01119625 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK1024850A
Description: Intramuscular injection, one dose
Study NCT01119625 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix-IPV/Hib
Description: Intramuscular injection, one dose
Study NCT01119625 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix-IPV/Hib
Description: Intramuscular injection, one dose
Study NCT04021407 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA group
Description: patients were ventilated with LMA
Study NCT04021407 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AirQ group
Description: patients were ventilated with AirQ airway
Study NCT02629640 — intervention group
Intervention type: OTHER
Intervention: Medical history questionnaire
Description: Epidemiological review of past medical/dental history; residential history; occupational history; family history of neurodegenerative disease.
Study NCT02629640 — intervention group
Intervention type: OTHER
Intervention: Clinical assessment and review
Description: History of current illness; neurological examination including general appearance, full cognitive assessment and physical examination; MRI research brain scan.
Study NCT02629640 — intervention group
Intervention type: OTHER
Intervention: Participant follow-up
Description: Hospital patient management system; regular telephone contact with patient/representative.
Study NCT02629640 — intervention group
Intervention type: OTHER
Intervention: Blood or buccal sample
Description: Codon-129 genotyping; storage for future research.
Study NCT02629640 — intervention group
Intervention type: OTHER
Intervention: Post mortem examination
Description: Brain tissue donation to the Edinburgh Brain and Tissue Bank for research,including investigations for evidence of prion disease.
Study NCT01721772 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-936558 (Nivolumab)
Study NCT01721772 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching BMS-936558 (Nivolumab)
Study NCT01721772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Study NCT01721772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching Dacarbazine
Study NCT04485819 — intervention group
Intervention type: OTHER
Intervention: Cleavage stage transfer
Description: transferring embryos through ICSI procedures for poor responders on cleavage stage of embryonic development.
Study NCT04485819 — intervention group
Intervention type: OTHER
Intervention: Blast stage transfer
Description: transferring embryos through ICSI procedures for poor responders on blast stage of embryonic development.
Study NCT04547036 — intervention group
Intervention type: DEVICE
Intervention: XEN45
Description: Up to 140 consecutive patients with preoperatively recorded endothelial cell counts will be summoned to a consecutive endothelial cell count record and measurement of central corneal thickness postoperatively.
Study NCT04280224 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK Cells
Description: twice a week of NK cells (0.1-2\*10E7 cells/kg body weight)
Study NCT02713139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clotrimazole + Metronidazole
Description: Vaginal cream with Clotrimazole 200mg and Metronidazole 0,75%. Apply once per day, before bedtime, for 5 (five) days.